IL219946A0 - Melanocortin-1 receptor-specific linear peptides - Google Patents

Melanocortin-1 receptor-specific linear peptides

Info

Publication number
IL219946A0
IL219946A0 IL219946A IL21994612A IL219946A0 IL 219946 A0 IL219946 A0 IL 219946A0 IL 219946 A IL219946 A IL 219946A IL 21994612 A IL21994612 A IL 21994612A IL 219946 A0 IL219946 A0 IL 219946A0
Authority
IL
Israel
Prior art keywords
melanocortin
receptor
linear peptides
specific linear
specific
Prior art date
Application number
IL219946A
Other languages
English (en)
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of IL219946A0 publication Critical patent/IL219946A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL219946A 2009-11-23 2012-05-23 Melanocortin-1 receptor-specific linear peptides IL219946A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26348609P 2009-11-23 2009-11-23
PCT/US2010/057700 WO2011063367A1 (en) 2009-11-23 2010-11-23 Melanocortin-1 receptor-specific linear peptides

Publications (1)

Publication Number Publication Date
IL219946A0 true IL219946A0 (en) 2012-07-31

Family

ID=44060072

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219946A IL219946A0 (en) 2009-11-23 2012-05-23 Melanocortin-1 receptor-specific linear peptides

Country Status (13)

Country Link
US (3) US8933194B2 (OSRAM)
EP (1) EP2504351A4 (OSRAM)
JP (1) JP2013511554A (OSRAM)
KR (1) KR20120102716A (OSRAM)
CN (1) CN102712674A (OSRAM)
AU (1) AU2010321739A1 (OSRAM)
BR (1) BR112012011780A2 (OSRAM)
CA (1) CA2781405A1 (OSRAM)
EA (1) EA201290295A1 (OSRAM)
IL (1) IL219946A0 (OSRAM)
MX (1) MX2012005859A (OSRAM)
WO (1) WO2011063367A1 (OSRAM)
ZA (1) ZA201203331B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2781402C (en) * 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
US9290539B2 (en) 2011-05-17 2016-03-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanotropin ligands for skin care
US9441013B2 (en) 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
US9402877B2 (en) * 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013138340A1 (en) 2012-03-13 2013-09-19 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
EP3328372A4 (en) 2015-07-28 2019-03-20 University Of Iowa Research Foundation COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
EP3523316B1 (en) * 2016-10-04 2021-11-03 DSM IP Assets B.V. Melanocortin-1-receptor agonists
CA3050630A1 (en) * 2017-02-01 2018-08-09 Clinuvel Pharmaceuticals Ltd Alpha-msh analogues used in the treatment of xeroderma pigmentosum
MX2020008590A (es) 2018-02-23 2020-09-21 Duke Univ & Medical Center El trasplante de tejido de timo cultivado promueve la tolerancia especifica de donante a los trasplantes alogenicos de organos solidos.
US11819520B2 (en) * 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US12364715B2 (en) 2018-02-23 2025-07-22 Enzyvant Therapeutics Gmbh Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma
WO2024040167A2 (en) * 2022-08-18 2024-02-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss
WO2025123059A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and uses thereof for treating substance use disorders
WO2025245258A1 (en) * 2024-05-21 2025-11-27 Endevica Bio, Inc. Non-naturally occurring melanocortin receptor agonist analogs for modulating weight gain

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731408A (en) 1985-12-20 1988-03-15 Polaroid Corporation Processable conductive polymers
DE3851002T2 (de) 1987-05-22 1995-02-02 University Patents, Inc., Westport, Conn. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
CA2275442A1 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
US5925618A (en) * 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
US6265162B1 (en) * 1998-05-05 2001-07-24 Taisei Corporation Method of identifying, detecting and monitoring microorganisms by an aromatic ring hydroxylase dioxygenase gene
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
DE69941877D1 (de) * 1998-10-16 2010-02-11 Otsuka Pharma Co Ltd Neovaskular-spezifische peptide
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
JP2002533111A (ja) 1998-12-23 2002-10-08 メルク エンド カムパニー インコーポレーテッド ヒトメラノコルチン１受容体タンパク質のスプライス変化体をコードするｄｎａ分子
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
KR100519201B1 (ko) 1999-03-29 2005-10-06 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드
WO2003006620A2 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7049398B1 (en) 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
EP1251865A1 (en) 2000-01-18 2002-10-30 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001251358A1 (en) * 2000-04-05 2001-10-23 V.I. Technologies, Inc. Prion-binding ligands and methods of using same
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
CN100491396C (zh) 2000-08-30 2009-05-27 霍夫曼-拉罗奇有限公司 选择性环肽
HUP0303085A2 (hu) 2000-09-27 2003-12-29 The Procter & Gamble Co. Melanokortin receptor ligandumok és ezeket tartalmazó gyógyszerkészítmények
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
CA2453027A1 (en) 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
US7328344B2 (en) 2001-09-28 2008-02-05 Imagitas, Inc. Authority-neutral certification for multiple-authority PKI environments
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US20030186249A1 (en) 2002-04-01 2003-10-02 Zairen Sun Human TARPP genes and polypeptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
US7655602B2 (en) * 2002-07-03 2010-02-02 Bio Science International, Inc. Peptides comprising aromatic D-amino acids and methods of use
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US20060122121A1 (en) 2002-11-14 2006-06-08 Lipton James M Modified alpha-MSH peptides and derivatives thereof
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
AU2004235872A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
AU2004251616A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
WO2005000338A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20070293423A1 (en) 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
JP2007532471A (ja) 2003-09-30 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ 新規メラノコルチンレセプターアゴニスト
CA2545644C (en) 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Melanocortin receptor agonists
EP1689349B9 (en) 2003-11-24 2014-02-26 Clinuvel Pharmaceuticals Limited A method of inducing melanogenesis in humans with mc1r variant alleles
US20070155660A1 (en) 2003-12-10 2007-07-05 Marsh Donald J Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
CA2557739A1 (en) 2004-03-29 2005-11-03 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
WO2005118573A1 (en) 2004-05-28 2005-12-15 Smithkline Beecham Corporation Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
NZ582130A (en) 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
US8569234B2 (en) 2004-10-08 2013-10-29 Clinuvel Pharmaceuticals Limited Compositions and methods for including melanogenesis in a subject
KR101255140B1 (ko) 2004-10-25 2013-04-22 얀센 바이오테크 인코포레이티드 멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도
JP2008519009A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
EP1809667A1 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
CN101052648A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
CN101052647A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新的肽类
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
CN101155825B (zh) * 2005-02-09 2014-11-26 赫里克斯生物医疗公司 抗微生物六肽
JP2008533101A (ja) 2005-03-17 2008-08-21 ノボ ノルディスク アクティーゼルスカブ 肥満の治療において使用するための化合物
AU2006253733A1 (en) 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Backbone cyclized melanocortin stimulating hormone (alpha S ) analogs
JP4734411B2 (ja) 2005-07-08 2011-07-27 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンド
US8349797B2 (en) 2005-07-08 2013-01-08 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
BRPI0613984A2 (pt) 2005-07-18 2011-03-01 Novo Nordisk As peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
US8466104B2 (en) 2005-08-26 2013-06-18 Abbvie Inc. Therapeutically active alpha MSH analogues
WO2007027574A2 (en) 2005-08-29 2007-03-08 Palatin Technologies, Inc. Cyclic peptide isolation by spray drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
JP2010517943A (ja) 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
JP2010516653A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
US8263583B2 (en) 2007-03-16 2012-09-11 Pfizer Limited Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
TW200848424A (en) 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
US20100329996A1 (en) 2007-09-12 2010-12-30 Glaxo Group Limited Novel Combination of Therapeutic Agents
CN101980717A (zh) 2007-11-05 2011-02-23 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
US20090305960A1 (en) 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
CA2727317C (en) 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011035205A2 (en) * 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides

Also Published As

Publication number Publication date
EP2504351A1 (en) 2012-10-03
ZA201203331B (en) 2013-07-31
MX2012005859A (es) 2012-12-17
US20170145056A1 (en) 2017-05-25
KR20120102716A (ko) 2012-09-18
US9580466B2 (en) 2017-02-28
CN102712674A (zh) 2012-10-03
WO2011063367A1 (en) 2011-05-26
JP2013511554A (ja) 2013-04-04
US20150119341A1 (en) 2015-04-30
US10106578B2 (en) 2018-10-23
EP2504351A4 (en) 2013-10-30
CA2781405A1 (en) 2011-05-26
US20120225831A1 (en) 2012-09-06
AU2010321739A1 (en) 2012-05-31
US8933194B2 (en) 2015-01-13
BR112012011780A2 (pt) 2019-09-24
EA201290295A1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
IL219946A0 (en) Melanocortin-1 receptor-specific linear peptides
IL219947A0 (en) Melanocortin-1 receptor-specific cyclic peptides
ZA201200128B (en) Melanocortin receptor-specific peptides
ZA201200112B (en) Melanocortin receptor-specific peptides
ZA201105852B (en) Antibiotic peptides
HUE041550T2 (hu) Lineáris mûködtetõ egység
PL2506741T3 (pl) Siłownik liniowy
PL2499397T3 (pl) Siłownik liniowy
GB2476465B (en) Recycling Technology
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
HRP20190262T1 (hr) Antimikrobni peptidi bazirani na cmap27
GB0910088D0 (en) Location arrangements
ZA201108446B (en) FViII-DERIVED PEPTIDES
ZA201203722B (en) Peptide
GB0921691D0 (en) Sophorolpid transporter protien
GB0905821D0 (en) Antimicrobial cyclic peptides
GB0901461D0 (en) Recycling
LT2494126T (lt) Izoliacinis brezentas
HK1169123A (en) Melanocortin receptor-specific peptides
GB0911790D0 (en) Peptides
IL214496A0 (en) Short b-defensin-derived peptides
GB0909494D0 (en) Neuroprotective peptide
GB0910466D0 (en) Fusion polypeptides
GB0910319D0 (en) Fusion polypeptides
GB0900852D0 (en) Tublar element